Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs

JAMA

Volumn 292, Issue 16, 2004, Pages 1955-1960

  Laheij, Robert J F ^a,b   Sturkenboom, Miriam C J M ^b   Hassing, Robert Jan ^b   Dieleman, Jeanne ^b   Stricker, Bruno H C ^b   Jansen, Jan B M J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CIMETIDINE; ESOMEPRAZOLE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; NIZATIDINE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; ROXATIDINE;

ADULT; AGED; AIRWAY OBSTRUCTION; ARTICLE; ASPIRATION PNEUMONIA; BACTERIAL COLONIZATION; BACTERIUM CONTAMINATION; CANCER; CLINICAL TRIAL; COHORT ANALYSIS; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DYSPEPSIA; FEMALE; FOLLOW UP; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL SYMPTOM; HOSPITAL INFECTION; HUMAN; INFECTION RISK; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PEPTIC ULCER; PRIORITY JOURNAL; SIDE EFFECT; STOMACH ACID SECRETION; STOMACH PH; UPPER GASTROINTESTINAL TRACT;

EID: 6944247563     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.292.16.1955     Document Type: Article

References (29)

1. Jones R, Lydeard S. Prevalence of symptoms of dyspepsia in the community. BMJ. 1989;298:30-32.
2. van Bommel MJ, Numans ME, de Wit NJ, Stalman WA. Consultations and referrals for dyspepsia in general practice, a one year database survey. Postgrad Med J. 2001;77:514-518.
3. Delaney BC, Innes MA, Deeks J, et al. Initial management strategies for dyspepsia. Cochrane Database Syst Rev. 2000:CD001961.
4. American Gastroenterology Association medical position statement and technical review: evaluation of dyspepsia. Gastroenterology. 1998;114:579-595.
5. Howden CW, Hunt RH. Relationship between gastric secretion and infection. Gut. 1987;28:96-107.
6. Giannella RA, Broitman SA, Zamcheck N. Influence of gastric acidity on bacterial and parasitic enteric infections. Ann Intern Med. 1973;78:271-276.
7. Thorens J, Froehlich F, Schwizer W, et al. Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study. Gut. 1996;39:54-59.
8. Ruddell WSJ, Axon ATR, Findlay JM, Bartholomew BA, Hill MJ. Effect of cimetidine on the gastric bacterial flora. Lancet 1980;8170:672-674.
9. Hayase Y, Tobita K, Sato H. Detection of type B influenza virus genes from biopsied gastric mucosa. J Gastroenterol. 2002;37:101-105.
10. Wickramasinghe LSP, Basu SK. Salmonellosis during treatment with ranitidine [unreviewed report]. BMJ. 1984;289:1272.
11. Brummer RJ, Stockbrugger RW. Effect of nizatidine 300 mg at night and omeprazole 20 mg in the morning on 24-hour intragastric pH and bacterial overgrowth in patients with acute duodenal ulcer. Dig Dis Sci. 1996;41:2048-2054.
12. Sanduleanu S, Jonkers D, de-Bruine A, Hameeteman W, Stockbrugger RW. Non-Helicobacter pylori bacterial flora during acid-suppressive therapy: differential findings in gastric juice and gastric mucosa. Aliment Pharmacol Ther. 2001;15:379-388.
13. Inglis TJ, Sherratt MJ, Spoat LJ, Gibson JS, Hawkey PM. Gastroduodenal dysfunction and bacterial colonization of the ventilated lung. Lancet. 1993;341:911-913.
14. Simms HH, de Maria E, McDonald L, Peterson D, Robinson A, Burchard KW. Role of gastric colonization in the development of pneumonia in critically ill trauma patients: results of a prospective randomized trial. J Trauma. 1991;31:531-536.
15. Laheij RJF, van Ijzendoorn MC, Janssen MJR, Jansen JBMJ. Gastric acid-suppressive therapy and community-acquired respiratory infections. Aliment Pharmacol Ther. 2003;18:847-851.
16. Vlug AE, van der Lei J, Mosseveld BM, et al. Post-marketing surveillance based on electronic patient records: the IPCI project. Methods Inf Med. 1999;38:339-344.
17. van der Lei J, Duisterhout JS, Westerhof HP, et al. The introduction of computer-based patient records in The Netherlands. Ann Intern Med. 1993;119:1036-1041.
18. Lamberts H, Wood M, Hofmans-Okkes IM. International primary care classifications: the effect of fifteen years of evolution. Fam Pract. 1992;9:330-339.
19. WHO Collaborating Centre for Drug Statistics Methodology. ATC Index With DDDs. Oslo, Norway: WHO Collaborating Centre for Drug Statistics Methodology; 2002.
20. Hurst AF. The clinical importance of achlorhydria BMJ. 1934;2:665-669.
21. Littman A. Potent acid reduction and risk of enteric infection. Lancet. 1990;335:222.
22. Martines AC, Tobal FG, Ruiz-Irastorza G, et al. Risk factors for esophageal candidiasis. Eur J Clin Microbiol Infect Dis. 2000;19:96-100.
23. Mikawa K, Akamatsu H, Nishina K, et al. The effects of cimetidine, ranitidine, and famotidine on human neutrophil functions. Anesth Analg. 1999;89:218-224.
24. Zedtwitz-Liebenstein K, Wenisch C, Patruta S, Parschalk B, Daxbock F. Graninger W. Omeprazole treatment diminishes intra- and extracellular neutrophil reactive oxygen production and bactericidal activity. Crit Care Med. 2002;30:1118-1122.
25. Aybay C, Imir T, Okur H. The effect of omeprazole on human natural killer cell activity. Gen Pharmacol. 1995; 26:1413-1418.
26. Scaringi L, Comacchione P, Fettucciari K, et al. Activity inhibition of cytolytic lymphocytes by omeprazole. Scand J Immunol. 1996;44:204-214.
27. Ruhl CE, Sonneberg A, Everhart JE. Hospitalisation with respiratory disease following hiatal hernia and reflux esophagitis in a prospective, population-based study. Ann Epidemiol. 2001;11:477-483.
28. Bartlett JG, Mundy LM. Community-acquired pneumonia. N Engl J Med. 1995;333:1618-1624.
29. Fine MJ, Smith MA, Carson CA, et al. Prognosis and outcomes of patients with community-acquired pneumonia: a meta-analysis. JAMA. 1996;275:134-141.